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Rapamycin in transplantation: A review of the evidence. The cytokines [for example, interleukin-2 (IL-2)] and pro-
calcineurin inhibitors have been the mainstays of immunosup- gression of the T-cell cycle from G0 to G1 [3]. Rapa has
pression for solid organ transplantation over the last two decades, a similar molecular structure to FK506 and also bindsbut nephrotoxicity limits their therapeutic benefit. Rapamycin
to FKBP12 [4]. However, the Rapa-FKBP12 complexis a new drug with both immunosuppressant and antiprolifera-
has no effect on calcineurin phosphatase. Instead, it bindstive properties that has a unique mechanism of action distinct
from that of the calcineurin inhibitors. It has a role as a mainte- to one or more proteins known as “targets of rapamycin”
nance immunosuppressant either alone or in combination with (TOR) [5]. These effector proteins were originally dem-
a calcineurin inhibitor and can also be used to treat refractory onstrated as TOR1 and TOR2 in yeast [6], but a mamma-acute rejection. Theoretical evidence suggests that it may limit
lian homologue has now been identified [7]. This hasthe development and progression of chronic rejection in trans-
been given a number of acronyms, including mTOR,plant recipients, but this has yet to be confirmed. This review
examines the current in vitro animal and human work underlying FRAP, SEP, and RAFT1 [7–10], but “mammalian target
the use of rapamycin and, in addition, comments on the pharma- of rapamycin” (mTOR) is most commonly used. Both
cokinetics and side-effect profile of this promising new agent. cytokines, such as IL-2 and the CD28/B7 costimulatory
pathway activate mTOR, resulting in downstream events
critical for cell cycle regulation (Fig. 1). This process is
Rapamycin (Rapa, Rapamune, Sirolimus; Wyeth-Ayerst complex and the underlying metabolic pathway has not
Pharmaceuticals, Philadelphia, PA, USA) is a macrocy- been fully characterized [11–15]. However, the Rapa-
clic fermentation product of Streptomyces hygroscopicus, FKBP12 complex binds mTOR and subsequently inhibits
an actinomycete, originally isolated from a soil sample both DNA and protein synthesis, resulting in arrest of the
in Rapa Nui (Easter Island, 1975) [1, 2]. Rapa was initially cell cycle in late G1 as it progresses to the S phase [16].
investigated as an antifungal and antitumor agent. How-
ever, its lymphopenic properties heralded its role as an
IMMUNOSUPPRESSIONimmunosuppressant. There is currently much interest in
Rapa because of its unique mechanism of action, lack In vitro
of end-organ toxicity, and its ability to synergize with The immunosuppressive properties of Rapa result from
other immunosuppressants, yet avoid overlapping side inhibition of leukocyte activity. It blocks T-cell prolifera-
effects. This review discusses the current evidence on tion induced by cytokines (IL-1, -2, -3, -4, -6, -7, -12,
which the use of Rapa in transplantation is based. and -15), alloantigens, and mitogens in a dose-dependent
manner [17–19]. However, Rapa does not appear to alter
IL-2 induced T-cell apoptosis (Abstract 73; Transplanta-MECHANISM OF ACTION
tion Society XVII, World Congress, Montreal, Canada,The mainstays of modern immunosuppression, Cyclo-
1998). Natural killer, cytokine-activated killer, and anti-sporin (CsA) and Tacrolimus (FK506), bind to the intra-
body-dependent cell cytotoxicity functions of human leu-cellular cytosolic immunophilins cyclophilin and FK
kocytes are suppressed by Rapa at concentrations 10- tobinding protein 12 (FKBP12), respectively, inhibiting
100-fold greater than those needed to block T-cell prolif-calcineurin phosphatase. This prevents transcription of
eration [20]. Rapa acts on B cells independently of its
effects on T helper cells, causing an inhibition of antigen
and cytokine driven B-cell proliferation [21]. In addition,Key words: acute rejection, side effects of transplantation, trough lev-
els, chronic kidney rejection, immunosuppression. it has been shown to inhibit cytokine-dependent (IL-2
and IL-6) differentiation into antibody-producing cells,Received for publication May 5, 2000
thus decreasing immunoglobulin synthesis [22].and in revised form July 27, 2000
Accepted for publication August 2, 2000 In contrast to the calcineurin inhibitors, it has been
claimed that Rapa has limited effects on cytokine expres-Ó 2001 by the International Society of Nephrology
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Fig. 1. Proposed mechanism of action for rapamycin. Abbreviations are: mTOR, mammalian target of rapamycin; IL, interleukin. Rapa inhibits
(1) Phosphorylation of 4E-BP1, preventing release of eIF-4E and initiation of translation [12, 13]; (2) P27-mediated activation of cdk2-cyclin E
and synthesis of proteins important for cell cycle progression [14]; and (3) p70S6 kinase activation, limiting ribosomal protein S6 phosphorylation
and reducing synthesis of ribosomal/translational proteins [15, 16].
sion in vitro. It does not inhibit the transcription of IL-2, relatively high doses of Rapa and CsA alone were re-
quired to inhibit cell-mediated lympholysis in vitro (IC50-3, -4 or tumor necrosis factor-a (TNF-a) in mitogen-
Rapa 5 8721 3 1029 M, CsA 5 1052 3 1029 M). How-activated T cells [17] and has been shown to have variable
ever, the same degree of inhibition was produced by aeffects on interferon-g (IFN-g) transcription dependent
combination of both at 72 and 144 3 1029 M, respectively.on the stimulus [23]. However, work comparing the ex-
In a further study, the IC50s required to inhibit thepression of TH1 and TH2 cytokines using reverse tran-
proliferation of an IL-2–dependent cell line for Rapa andscription-polymerase chain reaction (RT-PCR) in conca-
CsA alone were 90.9 and 2602 3 1029 M, respectively,valin A-stimulated spleen cells suggested that Rapa
compared with 65 and 260 3 1029 M when combinedinhibited the expression of IL-2, IFN-g, IL-4, and IL-10
[23]. This work has shown that the combination of Rapamore than nonimmunosuppressed controls [24]. Indeed,
and CsA is highly complimentary. Reduced doses ofRapa inhibited IL-10 expression more effectively than
both drugs achieve a response much greater than oneCsA (100 vs. 65% inhibition). Rapa’s main mode of
would expect from a purely additive effect, suggesting aaction is the inhibition of cytokine-activated signal trans-
synergistic interaction. The pharmacokinetic/pharmaco-duction, but clearly, any inhibitory effect on proinflam-
dynamic mechanisms underlying this are not clear. How-matory cytokine transcription (however minor) would
ever, this combination ensures that only small amounts
complement its immunosuppressive efficacy. The under- of cytokine are produced, causing reduced activation of
lying mechanism for this is not known but may stem from cytokine receptors and an attenuated downstream signal
the inhibition of costimulatory pathway transduction as that is more easily inhibited by Rapa. It was hoped that
this has been implicated in the transcriptional activation the combination of FK506 and Rapa would display simi-
of several cytokine genes. lar synergism. However, equimolar doses produced an
The concept of inhibiting cytokine transcription and additive effect, and if either was given in 50- to 1000-
simultaneously blocking cytokine-mediated signal trans- fold excess, they became antagonistic in vitro [26, 27].
duction has been investigated in vitro using CsA/Rapa
Animal studiescombinations. Rapa augmented the inhibitory effects of
CsA on antibody and phytohemaglutinin-stimulated pe- The first in vivo studies documenting the immunosup-
pressive properties of Rapa were published by Calne et alripheral blood leukocyte activation [25]. Furthermore,
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Table 1. Summary of the immunosuppressive efficacy of rapamycin alone at preventing graft loss secondary to the
development of acute rejection in animal allografts
Type of allograft Rapamycin dose Route of Maximum duration of treatment Mean number of days
Species [Reference] mg/kg/day administration days post-op unless stated graft survival . controls
Mouse Skin [30] 0.25–4 IP 6 4–5
Heart [29] 0.75–3.0/6.0 IP/PO 14 15–136/5
Rat Skin [31] 3.0 and 10.0 IM 8 6
Heart [31] 0.1–5.0 IM 11 9–1001
Heart [28] 0.5–5 IM 10 10–90
Heart [33] 0.04 IV 14 7
Heart [34] 0.16–0.8 IV 14 32–41
Heart [32] 0.25 IP 7a 45
Heart [35] 0.2–1.2 PO 30 13–55
Kidney [33] 0.01–0.04 IV 14 10–1001
Kidney [34] 0.8 IV 14 88
Kidney [35] 0.2–0.4 PO 30 2–6.5
Small bowel [34, 36] 0.8 IV 14 17
Pancreas [35] 0.2–0.4 PO 30 5–8
Pancreaticoduodenal [37] 0.8 IV 14 48
Rabbit Heart [38] 0.05–1.0 IV 60 . controlc
Dog Kidney [31] 0.3–1.5 IM Lifespan 2–10 , controlb
Kidney [39] 0.05 IV 7–20 16b
Kidney [40] 2.0 PO Days 3–5 1b
Pig Kidney [41] 0.25 IM 30 53
Kidney [40] 2 IM 64 65
Kidney [42] 0.1–2.0 PO 28 4–24
Baboon Kidney [43] 2–50 PO/IM/IV 15–20 0–30b
Abbreviations are: IP, intraperitoneal; PO, oral; IM, intramuscular; IV, intravenous.
a Preoperative administration only
b Severe gastrointestinal side effects
c Mean values not recorded
and Morris and Meiser [28, 29]. Both groups gave Rapa mg/kg/day) prolonged rat cardiac and kidney allograft
survival compared with either drug alone or the additiveat various doses to rats receiving heterotopic cardiac
allografts and noted longer graft and animal survival effect of a combination of both [33]. Similar results were
observed in studies using rat lung [47] and mouse kidneyrates in comparison to nonimmunosuppressed controls.
Similar benefits have been demonstrated for skin, renal, allografts [48] as well as a mongrel canine model [39].
In the preliminary investigation of Rapa (1991), asmall bowel, pancreatic, and pancreaticoduodenal allo-
grafts in a number of species, including mice, rats, rabbits, Rapa/FK506 combination acted synergistically in pro-
longing mouse heart tissue allograft survival [49]. How-pigs, dogs, and primates, although in dogs and primates
fatal gastrointestinal side effects frequently occurred ever, in vitro studies contradicted these findings and dis-
couraged investigators until relatively recently. In 1997,[28–43]. It is difficult to compare the immunosuppressive
efficacy of Rapa between studies as various doses, routes subtherapeutic doses of Rapa (0.02 to 0.04 mg/kg/day
intravenously) and FK506 (0.01 to 0.04 mg/kg/day intra-of administration, and allograft models have been used
(Table 1). However Rapa is 20 to 100 times more potent muscularly) in rat cardiac allografts not only prevented
the development, but also reversed active acute rejectionthan CsA and acted in a dose-dependent manner to
prevent acute allograft rejection. In studies that mea- [50]. The therapeutic combination index used confirmed
the efficacy of these agents with no evidence of the antag-sured trough levels, a range of 5 to 10 ng/mL provided
effective immunosuppression in small animals, but larger onism observed in vitro. Larger doses of oral Rapa (2 to
4 mg/kg/day) and intramuscular FK506 (2 to 4 mg/kg/animals required levels .10 ng/mL. Subsequently, Rapa
(0.8 mg/kg/day intravenously) was investigated as a po- day) demonstrated a similar extended survival in a
mouse small bowel allograft model [51]. The contradic-tential treatment for ongoing acute rejection and was
found to prolong the survival of presensitized rat skin tory findings in vitro and in vivo are difficult to reconcile.
However, only a small fraction of FKBP12 needs to beand cardiac allograft recipients [44]. This dose-depen-
dent effect (Rapa 0.08 to 0.8 mg/kg) was confirmed in occupied by either Rapa or FK506 in order to achieve
maximal immunosuppression [52]. FKBP12 is abundantcardiac, renal, and pancreas allografts with acute rejec-
tion [45, 46]. in vivo, and thus, competitive inhibition is unlikely to
be a problem [53]. In vitro, on the other hand, it is limited,The synergy between Rapa and CsA suggested in vitro
was also observed in animal work. Subtherapeutic doses and the opposite applies. In addition, it is possible that
these drugs have immunosuppressive mechanisms thatof Rapa (0.01 to 0.04 mg/kg/day) and CsA (0.5 to 2.0
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Table 2. A comparison of the results currently available from the ongoing multicenter trials
Rate of acute rejection (%)
Multicentre trial and One-year One-year Two-year Two-year
immunosuppression used 6 months 12 months allograft survival patient survival allograft survival patient survival
US
CsA/Aza/Pred (control) 24 93.8 98.1 91.3 96.9
CsA/Rapa 2 mg/Pred 12a 94.7 97.2 90.2 95.4
CsA/Rapa 5 mg/Pred 10a 92.7 96.0 90.1 94.9
Global
CsA/Placebo/Pred (control) 41.5 87.7 94.6 86.1 93.1
CsA/Rapa 2 mg/Pred 24.7a 89.9 96.5 85.5 93.0
CsA/Rapa 5 mg/Pred 19.2a 90.9 95.0 89.5 93.6
European/US
CsA/Rapa 2 mg/Pred 16.9 NA NA NA NA
1⁄2 CsA/Rapa (10–20 ng/ml)/
Pred 6 CsA elimination 18.5 NA NA NA NA
European 1
CsA/Aza Pred (control) 38 90 100 NA NA
Rapa/Aza/Pred 41 98 98 NA NA
European 2
CsA/MMF/Pred (control) 18.4 89.5 94.7 NA NA
Rapa/MMF/Pred 27.5 92.5 97.5 NA NA
Abbreviations are: CsA, Cyclosporin; 1⁄2 CsA, 1⁄2 dose Cyclosporin; Aza, azathioprine; Pred, prednisolone; MMF, mycophenolate mofetil; NA, not available.
a Statistically significant difference vs. control
are distinct from the FKBP12 complex [54]. However, patients receiving Rapa 2 mg/day had significantly higher
rates of acute rejection compared with non-African Ameri-these are not well understood at the present time.
cans (30.2 vs. 13.1%). Rapa 5 mg/day produced similarly
Human studies low rates of acute rejection that were less than controls
in both racial groups (14.8 vs. 11.3 vs. 28.6 to 30.3%),In September 1999, Rapa received approval from the
suggesting that this dose of Rapa should be used in Afri-U.S. Food and Drug Administration for marketing as
can American patients. Both Global and U.S. studiesan agent for the prevention of acute rejection in renal
had comparable graft and patient survival at one yeartransplant recipients. This was based on early results
for both 2 and 5 mg/day doses with little appreciablefrom several multicenter prospective randomized trials
attrition over the second year of follow-up (Table 2).(RCT) that are currently ongoing. These include a United
Similar, if not better, results were observed from a singleStates (N 5 719, 38 centers), a Global (N 5 576, 34
center (Houston, TX, USA) [55]. The same center inves-centers), a combined European-United States (N 5 247),
tigated the efficacy of a Rapa (0.5 to 7 mg/kg/m2])/CsA/and two European studies (N 5 83 and 78, 11 and 14
Pred regimen (N 5 43) versus CsA/Pred (N 5 126) incenters, respectively).
patients with IgG anti-human lymphocyte antigen panelBoth U.S. and Global studies administered combina-
reactive antibodies (PRA) .10%. These individuals havetions of Rapa (fixed dose 2 or 5 mg/day), CsA [and predni-
an increased risk of acute rejection and poor graft sur-solone (Pred)] in an attempt to take advantage of the
immunosuppressive synergy between these agents. The vival. There was a statistically significant reduction in the
frequency of acute rejection in those patients on RapaU.S. study gave azathioprine (Aza; 2 to 3 mg/kg) to
controls, whereas the global study gave a placebo. Two- (11.6 vs. 67%, P , 0.001), confirming the immunosuppres-
sive efficacy of CsA/Rapa combinations in high-risk re-year patient and graft survival data from both Global
and U.S. groups have been recently presented [Abstracts cipients (Abstract 155; AST/ASTS Meeting, May 2000).
The success of work combining full-dose CsA and957, 960, 962; American Society of Transplantation and
Transplant Surgeons (AST/ASTS), Chicago, IL, USA, Rapa encouraged the introduction of regimens that main-
tained the synergy between these agents yet minimizedMay 2000]. The incidence of acute rejection was clearly
reduced in both trials when patients received either 2 or nephrotoxicity and side effects. Most work has focused
on reducing CsA exposure, but one study has attempted5 mg/day of Rapa (Table 2). In addition, the severity of
acute rejection was reduced in patients receiving Rapa steroid withdrawal. One hundred forty-nine de novo re-
nal allograft recipients were randomized to receive Rapaat both doses, but this was only statistically significant in
the Global study. The additional benefit from the higher or placebo with the addition of either full- or half-dose
CsA (month 1 trough levels ,300 or ,200 ng/mL, re-(5 mg) dose of Rapa was small in both studies. However,
an analysis of the effect of race on the efficacy of Rapa spectively) and steroids [56]. The incidence of acute re-
jection within six months of transplantation in patientsin the U.S. study demonstrated that African American
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receiving full-dose CsA was reduced from 32 to 8.5% in thus, a period of underimmunosuppression can theoreti-
cally occur.patients receiving Rapa (1 to 3 mg/m2/day). Similarly low
rates of acute rejection (10.7%) occurred in Caucasians The withdrawal of steroids from CsA-based regimens
has caused high rates of acute rejection in the pasttreated with Rapa (1 to 5 mg/m2/day) and reduced-dose
CsA, but not in African Americans (39%), suggesting [59, 60]. A single-center prospective study withdrew ste-
roids from 124 patients on CsA/Rapa combinations athat this type of regimen is satisfactory for “low-risk”
recipients but is less acceptable for those at “higher risk.” mean of 437 days after transplantation (Abstract 423;
AST/ASTS Meeting, May 2000). At two years of follow-Those receiving reduced-dose CsA tended to have better
renal function compared with full-dose CsA recipients, up, only 4% had episodes of acute rejection, with 76.6%
remaining off from steroids. These individuals had stablebut this was only statistically significant at a Rapa dose
of 1 mg/m2/day, three months after transplantation. A renal function and a low incidence of chronic rejection,
indicating that this approach has significant potential,similar European/U.S. prospective multicenter study (N 5
247) currently ongoing compares full-dose CsA and particularly for pediatric transplant recipients.
The two major European, prospective, randomizedfixed-dose Rapa (2 mg/day) with reduced-dose CsA and
concentration-controlled Rapa (10 to 20 ng/mL; Abstract multicenter studies have adopted a different approach
to the use of Rapa [61, 62]. Both compared Rapa triple958; AST/ASTS Meeting, May 2000). The incidence of
acute rejection at two months was equally low (13.5 vs. therapy directly against CsA triple therapy in an attempt
to determine whether Rapa could replace CsA as the10.9%). However, the aim of this study was to withdraw
reduced-dose CsA from patients who had not rejected primary immunosuppressant for renal allograft recipi-
ents. Doses of both drugs were adjusted according toin the first three-months post-transplantation. This was
achieved in 51 out of 77 (66%) patients, and at six trough levels (CsA, 200 to 400 ng/mL for 2 months and
100 to 200 ng/mL thereafter; Rapa, 30 ng/mL for 2months, the incidence of acute rejection in both groups
was similar (Table 2) with significantly improved renal months and 15 ng/mL thereafter). The first study used
Aza (2 mg/kg) and Pred, whereas the second used myco-function in those who had CsA reduction/withdrawal
(mean creatinine 123 vs. 147 mmol/L). phenolate mofetil (MMF) 1 g twice daily and Pred as
additional agents. At one-year follow-up, graft survival,In contrast to the late elimination of CsA in low-risk
patients, one pilot study (N 5 6) has examined the effect patient survival, and incidence of acute rejection showed
no statistically significant differences when CsA wasof CsA exclusion in the immediate post-transplant pe-
riod in allografts with a high risk of delayed graft function compared with Rapa (Table 2). MMF combined with
either CsA or Rapa produced lower rates of acute rejec-[57]. On the basis of this work, a further trial in 24 patients
was undertaken (Abstract 571; AST/ASTS Meeting, May tion than these agents and Aza. However, even patients
on MMF and Rapa had a tendency to require treatment2000). A combination of anti-CD25 monoclonal anti-
body (Basiliximab; Novartis, Basel, Switzerland), Rapa for acute rejection with bolus steroids more often than
those on CsA and MMF (20 vs. 11, P 5 0.068). This(5 to 10 mg to maintain 5 to 20 ng/mL trough levels),
and Pred was used until serum creatinines fell below 2.5 suggests that there may be a small price to pay for com-
pletely avoiding the nephrotoxicity of CsA. However,mg/dL (166 mmol/L) when CsA was introduced. There
were three episodes of acute rejection, and 23 out of 24 the clinical significance of this is debatable as renal func-
tion tended to be better in Rapa-treated patients overallografts functioned 80 days to 20 months post-trans-
plantation with serum creatinine values below 2 mg/dL follow-up in both studies, although this was not statisti-
cally significant at all time points in either of the two(133 mmol/L) in 80% of the patients. Regimens avoiding
contributions made by CsA nephrotoxicity to delayed studies.
Currently, only one uncontrolled study has combinedgraft function in high-risk allografts may have significant
advantages over current therapeutic options. Non–heart- Rapa and FK506 in human transplantation [63]. Thirty-
two allograft recipients [liver (N 5 23), liver/kidneybeating organs with their well-documented ischemia-re-
perfusion injuries are obvious potential beneficiaries, but (N 5 2), pancreas (N 5 2), or pancreas/kidney (N 5 5)]
received Rapa 5 mg/day (3 to 7 ng/mL), FK506 0.03 mg/randomized controlled trials will be required to confirm
this observation. CsA dose reduction (80%) with the day (one third of the usual dose, 6 to 12 ng/mL), and
Pred with doses adjusted to trough levels. There wasaddition of Rapa has also been performed in established
delayed graft function [58]. Some, albeit impaired, renal 94% patient survival at 230 days and only one episode of
acute rejection in a noncompliant patient. Renal functionfunction was salvaged presumably because CsA nephro-
toxicity was reduced, while simultaneously maintaining was excellent, with mean serum creatinines of 93 and
112 mmol/L in hepatic and renal recipients, respectively.adequate immunosuppression. However, Rapa may not
be the best agent in these circumstances, as it takes The combination of low-dose FK506 and Rapa provided
good immunosuppression with minimal nephrotoxicityseveral days to achieve adequate therapeutic levels, and
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and should be investigated further in multicenter single was given to 30 stable renal transplant recipients taking
CsA at normal therapeutic doses with no significant ef-organ randomized controlled trials.
Rapa has also been used to treat refractory acute rejec- fects on GFR or creatinine clearance over a 14-day pe-
riod [71]. However, patients in the Global/U.S. studiestion not responding to either conventional pulsed steroid
or antilymphocyte preparations [64]. Patients (N 5 21) on Rapa tended to have higher serum creatinine levels
than controls. The decreased renal function has yet to bewere given Rapa (7 mg/m2 for 5 days, followed by 5 mg/m2
thereafter) with no change in CsA dose (Abstract 963; adequately explained. Currently, only one retrospective
single-center study has attempted to address this issue.AST/ASTS Meeting, May 2000). Ninety percent of patients
had successful reversal of rejection producing an actuar- CsA average concentrations (CAV) and Rapa trough lev-
els (TL; 655 samples, 96 patients) were compared withial one-year graft survival of 81%. These individuals had
a mean serum creatinine of 2.4 mg/dL (160 mmol/L) at the calculated GFR at each time point (Abstract 156;
AST/ASTS Meeting, May 2000). Increasing Rapa expo-one year. Refractory rejection often has a poor progno-
sis, with many patients requiring dialysis. These results sure was not associated with decreased renal function.
However, as Rapa TLs increased the CsA, CAV necessaryprovide reason for optimism, but larger studies are neces-
sary to confirm these findings. to achieve optimal renal function fell. Further prospec-
tive studies are clearly required to determine whether
Rapa does indeed increase CsA concentrations or whether
NEPHROTOXICITY OF RAPAMYCIN
the CsA/Rapa combination causes an independent phar-
Cyclosporine A and FK506 have their therapeutic ben- macodynamic effect.
efit limited by acute and chronic nephrotoxicity. Cal-
cineurin phosphatase inhibition is thought to be respon-
SIDE EFFECTS OF RAPAMYCINsible for both afferent renal vasoconstriction and the
release of cytokines that are responsible for these changes. Rapa is poorly tolerated by certain species. Dogs given
Rapa at low doses (0.05 mg/kg/day) developed anorex-Rapa has a different mechanism of action, and thus, the
nephrotoxicity seen with calcineurin inhibition does not ia, fever, vomiting, leukocytosis and hyperamylasemia.
occur. Higher doses (0.3 to 2.0 mg/kg/day) are often fatal and
However, supratherapeutic doses of Rapa (1.5 to 10 autopsy findings suggest that Rapa produces a submuco-
mg/kg/day) may cause small reductions in creatinine sal vasculitis with mucosal erosion/ulceration [31, 39, 40].
clearance in rat native kidneys [65–67]. Work in both A similar but less frequent syndrome occurs in baboons
pigs (0.1 to 0.4 mg/kg) and rats (5 mg/kg/day) has shown [43] but is not seen in other species. In certain rat models,
that Rapa has no deleterious effects on glomerular filtra- Rapa has been linked with myocardial necrosis, but pre-
tion rate (GFR) or renal blood flow (RBF) and caused existing parvovirus infection is now thought to be respon-
minimal morphological signs of toxicity [67, 68]. Rapa sible for this observation.
reduced medullary concentrating ability and increased Regular administration of Rapa produces a number
tubular enzymuria in rat kidneys, suggesting that mild of side effects in humans. These can occur at low daily
tubular injury may occur [69]. In humans, pooled data doses (1 to 21 mg/day) and include headaches, poly-
from both European trials comparing Rapa with CsA arthralgia, mild stomatitis, epistaxis, diarrhea, and skin
triple therapy showed a statistically significant improve- complaints, for example, mild acne. However, myelosup-
ment in both serum creatinine and calculated GFR at pression, hyperlipidemia, and problems related to over-
two years of follow-up in Rapa patients (mean creatinine immunosuppression remain the major concerns.
,120 mmol/L and mean GFR .65 mL/min). This sug-
Myelosuppressiongested that even if Rapa caused mild tubular damage, it
had little clinical significance (Abstract 848; AST/ASTS This was first observed in mice when Rapa delayed
recovery from 5-fluorouracil-induced leukopenia andMeeting, May 2000). However, controversy exists as to
whether Rapa potentiates CsA nephrotoxicity. In a salt- thrombocytopenia in a reversible manner [72]. The un-
derlying mechanism is unknown, but may relate to inhibi-depleted rat model of CsA toxicity, this combination
produced a functional and morphological deterioration tion of signal transduction from hematological growth
factor receptors that have sequence homology with the[70]. However, it is difficult to interpret the relevance of
these findings, as high CsA trough levels (maximum 2850 cytokine receptors whose action is inhibited by Rapa
(for example, the IL-11 receptor that stimulates plateletng/mL) were assessed but Rapa levels were not. A study
in the Wistar-Firth rat suggested that the observed de- production has the same gp130 b chain as the IL-2 recep-
tor [73, 74]).crease in GFR could be ascribed to a Rapa-related in-
crease in CsA concentrations, but work is necessary to Rapa produced a dose-dependent reversible thrombo-
cytopenia in stable renal transplant recipients within twocharacterize this further (Abstract 206; AST/ASTS Meet-
ing, May 1999). In humans, Rapa (1 to 13 mg/m2/day) weeks that persisted but improved over treatment. Rapa
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doses of 1 to 3, 5 to 6, and 7 to 13 mg/m2/day reduced levels, respectively, with few serious clinical consequences.
Hypertriglyceridemia can be severe with CsA/Rapa regi-mean platelet counts by 14, 80, and 97 cells/mm3, respec-
tively. A reversible leukopenia also occurred, with a mens (11.7 to 42 mmol/L), particularly at higher Rapa
doses, but is reversible after dose reduction or cessationmean reduction of approximately 2 cells/mm3 for all
Rapa doses [71]. The European multicenter (Aza/MMF) of Rapa [78]. However, discontinuation of Rapa in the
Global/U.S. trials was rare (0.4% Rapa 2 mg, 2.5% Rapastudies documented thrombocytopenia in 37 and 45%
of Rapa patients (controls 0 and 8%, respectively, P , 5 mg). Analysis of one-year cholesterol values using The
Framingham Model suggested that Rapa would cause only0.05). Thirty-nine percent on Rapa/Aza/Pred had leuko-
penia (control 14%, P , 0.05), but in those receiving a small increased incidence of ischemic heart disease in
renal transplant recipients (2 and 3 new cases/1000 per-MMF, there was no significant difference between Rapa
and controls (28 vs. 18%). CsA/Rapa combinations pro- sons/year; Rapa 2 and 5 mg, respectively). Dose reduction
or elimination of CsA from Rapa patients may reduceduced a similar incidence and severity of leukopenia/
thrombocytopenia that correlated with Rapa TLs (dis- this risk further, and results are awaited with interest.
FK506 may be less lipogenic than CsA, and thus, com-cussed later) [55]. Patients taking Rapa/CsA recovered
from a low hemoglobin after transplantation less effec- bination with Rapa may produce less frequent and severe
hyperlipidemia. Serum Chol and TGs were elevated (Choltively than controls.
Myelosuppression has not proved to be a significant 5.8 mmol/L, TGs 4.6 mmol/L), but only one patient re-
quired treatment in an initial pilot study [63]. Hyperlipid-clinical problem in the majority, but may become patho-
logical in a small minority of patients. Rapa dose reduc- emia appears less marked than with Rapa/CsA combina-
tions, but a randomized trial to compare these regimenstion or discontinuation causes initial signs of recovery
usually apparent within five days. If anemia is severe, is necessary to confirm this preliminary data.
subcutaneous erythropoietin can supplement this in the
Overimmunosuppressionshort term until the hemoglobin is acceptable.
Overimmunosuppression predisposes patients to both
Hyperlipidemia typical/atypical infections as well as increasing the risk
of neoplasia and post-transplant lymphoproliferative dis-Both calcineurin inhibitors and steroids promote hy-
perlipidemia [75], glucose intolerance [76], and hyperten- ease (PTLD). The European (Aza) study noted a higher
incidence of herpes simplex (24 vs. 10%, P 5 0.08) andsion [77], which are well-recognized risk factors for the
development of cardiovascular disease. In contrast, Rapa pneumonia (17 vs. 2%, P 5 0.03) in Rapa patients com-
pared with controls [61]. However, when MMF replacedhas little influence on blood pressure or serum glucose
concentrations, and an early study in pigs reported that Aza as the secondary agent, the incidence of herpes
simplex was similar in both Rapa and control patients,hyperlipidemia was mild and similar to that observed
with CsA [41]. Human phase I studies were also encour- and although an increased incidence of pneumonia oc-
curred, it was not statistically significant (15 vs. 5%) [62].aging with only higher Rapa doses (5 to 13 mg/m2/day)
causing statistically significant hypercholesterolemia and The multicenter trials combining CsA and Rapa reported
similar significant increases in herpes simplex infectionsno significant effects on triglycerides [73]. However,
these data only reflected a 15-day course, and longer (Global) and pneumonia (United States). However, the
incidence of life-threatening infections and CMV wasadministration has shown a different picture.
The European (Aza) study comparing Rapa and CsA not increased despite the immunosuppressive synergism
between these drugs. The study combining FK506 andtriple therapy noted that Rapa caused significantly more
frequent and severe hypercholesterolemia and hypertri- Rapa anecdotally stated that the rate and severity of
bacterial/viral infection were lower than that usually seen,glyceridemia than CsA (44 vs. 14% and 51 vs. 12%,
respectively). Hyperlipidemia was maximal after two but no data were presented to substantiate this observa-
tion [63].months [triglycerides (TGs) 5.3 vs. 2.1 mmol/L, P ,
0.001, cholesterol (Chol) 9.2 vs. 6.4 mmol/L, P , 0.001] Clinical use of Rapa is still at an early stage, and
its impact on PTLD is currently unknown. Kahan haswhen Rapa target levels were high (30 ng/mL), but as
these were reduced (15 ng/mL), this improved (6-month followed up 250 patients treated with Rapa (3 to 48
months) and noted only two cases of PTLD (0.8%) [58], aTG, 3.6 vs. 1.6 mmol/L, P 5 0.007; 6-month Chol, 6.9
vs. 6.1 mmol/L, P 5 0.15) [61]. A combined analysis of statistic comparable to the general transplant population
[79]. Multiple small bowel segments were involved inboth U.S. and Global studies has shown a similar picture.
Rapa produced a dose-related increase in Chol and TGs one and nuchal lymph nodes in the other. Rapa with-
drawal and CsA dose reduction resulted in remissionby three months that was persistent but reduced after
one year of follow-up (Abstract 955; AST/ASTS Meeting, with both patients alive and well 6 and 36 months later,
respectively. A two-year follow-up of 1295 patients fromMay 2000). The use of statins/fibrates was effective in
the majority, causing significant decreases in Chol/TG the Global and U.S. trials showed that only two patients
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(0.7%) died as a result of neoplasia. Neither European most would agree that 5 ng/mL is a safer estimate of the
lower end of Rapa’s “therapeutic window” [87]. Thismulticenter study reported a case of neoplasia. Rapa has
antiproliferative properties and was initially investigated may not apply in high-risk patients, for example, African
Americans who may need to have levels nearer 15 ng/mLas an antitumor agent (Abstract 141; Cold Spring Har-
bour Meeting on Cell Cycle, New York, May 1994). How to maintain a low incidence of acute rejection. The upper
end of the therapeutic window aims to minimize toxicity.this will affect the predisposition to neoplasia caused by
its immunosuppressive efficacy will only become appar- The distribution frequencies for platelet count, Chol and
TGs by Rapa concentration ranges suggested levels ofent over long-term follow-up.
.15 ng/mL were associated with the greatest derange-
ment. A study from Houston documented a linear corre-
THERAPEUTIC MONITORING OF RAPAMYCIN
lation between these side effects and Rapa trough levels
Rapa, currently only available in liquid formulation, [55]. Rapa levels .15 ng/mL caused a 25% fall in platelet
has a relatively low bioavailability (14 to 15%) with sig- count and a 50% increase in TGs compared with Rapa
nificant interindividual and intraindividual pharmacoki- levels ,5 ng/mL, supporting the use of 15 ng/mL as a
netic differences. It has a long half-life (approximately sensible upper limit.
63 hours), justifying both a loading dose to rapidly attain The successful reduction in acute rejection associated
steady-state concentrations and once-daily dosing. A with fixed Rapa doses of 2 and 5 mg/day in the U.S.
solid formulation (currently unlicensed) has a compara- and Global trials suggests that while desirable, routine
ble bioavailability with similar safety and efficacy param- monitoring of Rapa levels in such regimens is not essen-
eters (Abstracts 157, 158, and 159; AST/ASTS Meeting, tial, particularly at doses of 2 mg/day. However, monitor-
May 2000). Conversion from liquid to solid “tablet- ing is probably necessary to ensure safe, effective concen-
based” Rapa was safe and easily achievable [80]. trations in (1) the early period post-transplantation to
Analysis of the U.S. and Global trials has shown that confirm that levels are not at the extremes of the ex-
although mean Rapa levels were related to the Rapa pected range [two determinations within the first two
dose, there was wide overlap in Rapa trough levels over weeks are advised due to the intraindividual variability
the 2.5-fold dose range used [Rapa 2 mg, 8.06 to 8.59 in Rapa pharmacokinetics; if a dose change is necessary,
(6 4.01 to 4.03), range 2.34 to 31.30 ng/mL; Rapa 5 mg, a further assessment should be made when a new steady
17.3 (6 7.35 to 8.20), range 4.85 to 50.90 ng/mL; mean state has been attained (5 to 7 days after dose change)];
(6 SD)]. This is thought to be due to the combined (2) after the introduction/discontinuation of CYP 3 A4/
action of the P450 cytochrome (CYP) 3A4 responsible P-glycoprotein inhibitors/inducers to ensure safe, effec-
for the metabolism of Rapa and the multidrug efflux tive concentrations; (3) patients in whom CsA dose or the
pump, p-glycoprotein [81]. These are located in the liver relative timing of Rapa/CsA doses is altered significantly;
and small bowel. Biopsies have shown that there is wide (4) there are signs of toxicity, for example, hyperlipid-
variability in the intestinal content of these proteins [82]. emia, or a change in clinical condition, for example, de-
In addition, the activity of both is affected by coadminis- velopment of liver disease; and (5) in patients in whom
tration of drugs such as CsA. In rats, both CsA and Rapa noncompliance is suspected. Closer monitoring of Rapa
trough levels were increased when these were combined levels is recommended in patients at high risk of rejec-
[83]. In humans, however, the quantitative effects of tion, children, and those with hepatic impairment.
this interaction are less clear. One study in stable renal The problem currently facing clinicians using Rapa is
transplant recipients demonstrated that the relative tim- that most centers do not have a validated method to
ing of administration was important [84]. When CsA and analyze Rapa levels, and therefore, samples are sent
Rapa were administered together, Rapa exposure was to reference laboratories. This can introduce significant
50% higher than when they were given four hours apart. delays, making patient management cumbersome. Meth-
The timing of administration did not affect CsA levels. ods with a faster turnaround need to be developed or
Further studies are required to characterize this relation- centers will have to introduce techniques locally. There
ship more extensively. are currently four published techniques to monitor Rapa
A good correlation exists between Rapa trough levels levels. The gold standard is high-performance liquid
and the more accurate assessment of drug exposure, area chromatography with mass spectrometric (HPLC-MS)
under the concentration curve [85]. Therefore, current detection, but this is expensive, not widely available, and
recommendations for monitoring Rapa are based on requires significant operator expertise [88]. HPLC with
trough levels. Regression analysis of data from the U.S. ultraviolet detection is available in many laboratories,
and Global trials has suggested that in order to minimize and several methods have shown a good correlation with
the risk of acute rejection, Rapa levels should not fall HPLC-MS, supporting its use in a clinical setting [88].
below approximately 3.5 ng/mL during concomitant ad- However, it is quite time consuming, taking between 12
and 14 hours to process 24 samples. Therefore, the useministration of full-dose CsA and steroids [86]. However,
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of microparticle enzyme immunoassays (MEIAs), which (2) Intimal hyperplasia (often associated with CR) is a
stereotyped response of the endothelium to both immunecan analyze 24 samples within two hours thus facilitating
a rapid turnaround, has been advocated [89]. Although and nonimmune injury. Rapa treatment reduced the de-
gree of intimal thickening and associated local cytokinethis is able to measure Rapa levels within the therapeutic
range, it is not specific for Rapa alone, detecting Rapa expression at doses of 1.5 mg/kg/day after mechanical
injury (angioplasty balloon catheter). However, it wasmetabolites that have little biological activity. Therefore,
when compared with HPLC, MEIA produces a positive initially thought to be ineffective at this dose in a femoral
allograft model of immune injury [107]. These findingsbias of approximately 20%. The practical significance of
this remains to be assessed. Immunophilin binding assays were criticized because the intimal hyperplasia was ana-
lyzed near the suture line of femoral allografts and thus(IBAs), although showing weak Rapa metabolite cross-
reactivity, correlate with HPLC values, are easier to per- may have been excessive. On re-evaluation of the central
part of femoral allografts, intimal hyperplasia was re-form, and have the potential to be automated [90]. Since
an automated system will ultimately be required as Rapa duced by 1.5 mg/kg/day Rapa, as seen in the mechanical
model [108]. Rapa was most effective at higher dosesuse becomes widespread, this may offer a good option
for the future. However, the field is evolving rapidly and (6 mg/kg/day), but lower dose Rapa (1.5 mg/kg/day) in
combination with MMF was also highly effective aftertechniques such as monitoring Rapa levels by p70 S6
kinase inhibition are under development [91]. balloon catheter damage. Administration of Rapa and
MMF for 14 days after injury inhibited intimal hyperpla-
sia at day 14, but by day 40, intimal hyperplasia had
CHRONIC REJECTION
returned and was similar to untreated controls. However,
The histology of chronic allograft rejection (CR) is if administered 3 days before and 14 days after insult,
dominated by the accumulation of extracellular matrix. there was little intimal hyperplasia observed at day 40
This is characterized by intimal hyperplasia, a concentric [109], presumably as sufficient concentrations were pres-
vasculopathy, and interstitial fibrosis in addition to or- ent to dampen the initial cytokine cascade immediately
gan-specific changes that may reflect the effects of ische- after injury, generating a smaller intimal response that
mia secondary to this initial vascular involvement [92]. resolved with few sequelae. These studies show that the
It is thought that early endothelial damage initiates a vascular response to both immune and nonimmune in-
cascade of growth factor production, for example, trans- jury is inhibited by Rapa, but the interplay between the
forming growth factor-b (TGF-b) and platelet-derived antiproliferative and immunosuppressive properties that
growth factor (PDGF) [93, 94], resulting in recruitment contribute to this is unclear. On one hand, the balloon
and proliferation of inflammatory cells, smooth muscle injury model lends support to an antiproliferative theory.
cells, and fibroblasts with an ensuing up-regulation of On the other, Rapa (3 mg/kg/3 times/week) prevented
extracellular matrix deposition and scarring [95, 96]. A both acute rejection and arteriosclerotic changes in rat
number of lines of evidence suggest that Rapa may theo- aortic allografts [110]. The positive correlation noted
retically influence the course of CR. between acute rejection and graft arteriosclerosis sug-
(1) Rapa inhibits growth factor-mediated proliferation of gested that immunosuppressive effects were also impor-
cells involved in the pathogenesis of CR in vitro. This anti- tant in the attenuation of vascular injury.
proliferative effect is seen in nonstimulated as well as At the molecular level, rat aortic allografts treated
basic fibroblast growth factor (bFGF), insulin-like growth with Rapa (0.5 mg/kg/day) had little intimal hyperplasia
factor-1 (IGF-1), and PDGF-driven vascular smooth but significant inducible nitric oxide synthase (iNOS)
muscle cells [97–99], and was greater with Rapa than expression at 30 days. In contrast, CsA treatment was
MMF or FK506 [100]. Rapa exerted similar effects on associated with marked intimal hyperplasia but no de-
bFGF-induced bovine aortic and human umbilical vein tectable iNOS expression [111]. Nitric oxide (NO) inhib-
endothelial cells as well as PDGF/bFGF-stimulated rat ited the proliferation of vascular smooth muscle cells in
cardiac and human lung fibroblasts [100–103]. These both balloon-injured and aortic allograft models, and
antiproliferative properties were antagonized by combi- also prevented the development of arteriosclerosis [112,
nation with FK506 in molar excess, suggesting that the 113]. Thus, one possible explanation for Rapa’s actions
formation of the Rapa/FKBP12 complex is an important is that iNOS expression is maintained, causing high local
underlying mechanism [104]. However, Rapa does not NO levels that limit vascular smooth muscle responses
uniformly inhibit cell proliferation. Some hematopoietic to injury. Future work combining Rapa with selective
and epidermoid cell lines are unaffected by its adminis- iNOS inhibitors will delineate this process further.
tration [105, 106]. In addition, there is currently little Rapa also reduced the severity of established intimal
evidence that Rapa inhibits cell proliferation stimulated hyperplasia in rat femoral artery allografts when given
by arguably one of the most important cytokines in the 14, 21, and even 30 days after the onset of alloimmune
injury [108]. However, larger Rapa doses were requireddevelopment of CR: TGF-b.
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(3 to 6 mg/kg/day), and intimal hyperplasia was most proliferative effect causing the reduction in GVD. As
with models of vascular injury, both the antiproliferativesuccessfully reduced when Rapa was added at an early
stage, that is, when intimal hyperplasia was relatively and immunosuppressive properties of Rapa seem impor-
tant in the prevention of CR in cardiac allografts. How-immature. A similarly large dose of Rapa (6 mg/kg/day)
prevented the development of obliterative bronchiolitis ever, further work using renal allografts and some of the
better characterized growth factors linked with CR, for(compare CR) in rat tracheal allografts more effectively
than CsA or MMF. No luminal fibrosis or loss of respira- example, TGF-b, PDGF, bFGF, is required to determine
the magnitude of these benefits for renal transplant re-tory mucosa was demonstrated [114], suggesting that
Rapa may have extravascular as well as intravascular cipients.
(4) Underimmunosuppression and severe, recurrent, oreffects in certain models.
(3) The effect of Rapa on CR in whole organs has been late episodes of acute rejection are risk factors for CR.
Rapa has been shown to be a powerful and effectiveinvestigated in rat cardiac allografts where it is manifested
as graft vessel disease (GVD). Meiser, Billingham, and immunosuppressant, particularly in combination with
CsA, where both rates and severity of acute rejectionMorris were the first to observe that Rapa inhibited GVD
in such circumstances [115]. Further work has shown that were lower than controls. This may have a significant
impact on the incidence of CR in the future, but onlyinhibition of transplant vasculopathy and graft vessel
luminal obstruction secondary to myointimal changes long-term follow-up will confirm its efficacy.
(5) CsA causes chronic nephrotoxicity, generating both(100 days postoperatively) was most effective when Rapa
was given at high doses (5 mg/kg/day for 14 days followed fibrotic changes and an up-regulation of profibrotic cyto-
kines that can be indistinguishable from those of CR.by 2.5 mg/kg/day thereafter) [116]. Lower Rapa doses (0.5
and 2 mg/kg/day) were less effective but did still produce Rapa is non-nephrotoxic and has the potential to allow
early dose reduction or elimination of CsA, limiting thea significant reduction in vasculopathy (control 59 6 7%
vs. Rapa 0.5 mg/kg/day 25 6 15% vs. Rapa 2 mg/kg/day adverse effects of this drug on the development of CR.
Such studies have recently been instituted and have been22 6 11%). The addition of Rapa (0.5 mg/kg/day) to low-
dose CsA (1.5 mg/kg/day) for 14 days reduced lym- discussed earlier in this article. However, it will be sev-
eral years before meaningful data with respect to CRphocytic infiltration but did not cause an additional
reduction in vasculopathy. The immunosuppressive syn- become available. Studies using surrogate markers, for
example, RT-PCR of profibrotic genes and computer-ergism between these agents appeared to have little ben-
eficial impact on GVD at the low doses used over this ized histomorphometry of fibrosis of protocol biopsies,
may allow a prediction of Rapa’s impact on CR in theshort time period. However, the combination of CsA
(15 mg/kg/day) and Rapa (1 mg/kg/alternate days) for interim [121].
Patients with established chronic allograft nephropa-12 weeks after rat cardiac allografting reduced the fre-
quency and severity of both acute rejection and GVD thy who have 40 to 50% CsA dose reductions with the
addition of Aza or MMF can have significant improve-compared with CsA alone [117]. Rapa/CsA allografts
showed sparse infiltration of inflammatory cells, little ments in renal function [122, 123]. A similar CsA reduc-
tion with the addition of Rapa may also be beneficial.expression of adhesion molecules, no expression of
IFN-g/TNF-a and little GVD. These findings suggest A small prospective randomized trial (N 5 31) compared
a 40% CsA dose reduction alone to the same CsA dosethat the synergism between Rapa and CsA plays an im-
portant role in the inhibition of chronic rejection, contra- reduction with the addition of Rapa 2 mg/day in patients
with chronic allograft nephropathy (Abstract 432; AST/dicting earlier work. Wasowska et al confirmed these
findings [118] and also investigated the expression of ASTS Meeting, May 2000). Over a six-month period,
renal function was not improved by the addition of Rapa.monocyte associated chemokines involved in the devel-
opment of arteriosclerosis [119]. The expression of IL-12, A study including larger numbers of patients with a
longer follow-up is required to provide more definitiveMCP-1, and RANTES were significantly decreased by
CsA/Rapa therapy, providing further evidence that the evidence in this respect.
There are two problems with the hypothesis that Rapasynergism between these drugs may be beneficial in
GVD. may prevent/limit CR in humans. First, although the
pathogenesis of CR is multifactorial, hyperlipidemia mayRats with established cardiac GVD received Rapa 3
mg/kg/day over a 30-day period two months after trans- play a role [124]. Oxidized low-density lipoprotein (LDL)
is toxic to endothelial cells and induces endothelial andplantation in order to determine whether this process
was reversible [120]. Rapa compared with an equipotent smooth muscle cell proliferation as well as macrophage
differentiation into foam cells in vitro. Animals with fattydose of CsA led to a significant reduction in GVD, al-
though the overall level of graft inflammation and peri- acid deficiencies are protected from CR, but the addition
of large amounts of dietary cholesterol accelerates thevascular infiltrate was similar, implying analogous levels
of immunosuppression. Presumably Rapa had an anti- development of proliferative vascular lesions [125]. In
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12; GFR, glomerular filtration rate; GVD, graft vessel disease; HPLC-humans, there are several studies documenting an associ-
MS, high-performance liquid chromatography-mass spectrometry;
ation between hyperlipidemia and CR [124]. Rapa is IBA, immunophilin binding assay; IFN-g, interferon-g; IGF-1, insulin-
like growth factor-1; IL, interleukin; iNOS, inducible nitric oxide syn-known to cause hyperlipidemia in a dose-dependent
thase; MEIA, microparticle enzyme immunoassays; MMF, mycophe-manner. The therapeutic benefits of Rapa with respect
nolate mofetil; mTOR, mammalian target of rapamycin; NO, nitric
to CR may be reduced by this tendency. Hyperlipidemia oxide; PDGF, platelet-derived growth factor; PRA, panel reactive anti-
bodies; Pred, prednisolone; PTLD, post-transplant lymphoproliferativecan usually be corrected by appropriate medication.
disease; Rapa, Rapamycin; RBF, renal blood flow; RCT, randomizedHowever, starting patients on one drug to counteract
controlled trials; RT-PCR, reverse transcription-polymerase chain re-
the effects of another raises the issue of poly-pharmacy, action; TGs, triglycerides; TGF-b, transforming growth factor-b; TL,
trough levels; TNF-a, tumor necrosis factor-a; TOR, target of rapa-which can produce significant side effects as well as incur-
mycin.ring substantial costs that may or may not be justified
by improved long-term outcome.
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